Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Urol Oncol ; 34(6): 271-8, 2016 06.
Article in English | MEDLINE | ID: mdl-27108225

ABSTRACT

INTRODUCTION: Standard therapy for muscle invasive bladder cancer includes neoadjuvant chemotherapy followed by radical cystectomy with urinary diversion. Three decades of interest in primary radiation and chemotherapy for bladder preservation have yielded mature that deserve closer examination. METHODS: We reviewed the literature with an emphasis on outcomes from major clinical trials and prospective studies, while highlighting important aspects of effective treatment delivery and unanswered questions surrounding this approach. RESULTS: There are no randomized trials comparing radical cystectomy to primary chemotherapy and radiation for bladder preservation, and future phase III comparisons are unlikely to be planned. Mature results from single institution protocols and phase II cooperative group trials demonstrate favorable disease-specific survival and bladder preservation rates. Here we review the results of relevant clinical trials, including cancer-related and patient functional outcomes. We outline multi-modal treatment specifics with respect to radiation delivery, incorporation of transurethral resection and chemotherapy selection, and future directions for optimizing results of non-operative strategies. CONCLUSIONS: Combination chemotherapy and radiation can be used as an alternative to conserve the native bladder in appropriately selected patients, mirroring successful non-operative treatment paradigms used for organ-preservation for other cancer sites.


Subject(s)
Organ Sparing Treatments/methods , Urinary Bladder Neoplasms/therapy , Chemoradiotherapy , Clinical Trials as Topic , Combined Modality Therapy , Cystectomy , Humans , Neoplasm Invasiveness , Prospective Studies , Urinary Bladder Neoplasms/pathology
3.
Vet Microbiol ; 168(2-4): 272-80, 2014 Jan 31.
Article in English | MEDLINE | ID: mdl-24315042

ABSTRACT

Two field studies were conducted to investigate the influence of age on the efficacy of vaccination against Porcine Circovirus Diseases (PCVD) in animals with high levels of maternally derived antibodies (MDA). A total of 416 piglets (Study 1) and 600 piglets (Study 2) were randomly allocated to one of three groups. Two groups in each study received a single dose of a PCV2 subunit vaccine, one group at 1 week old and the other at 3 weeks of age. The third group was left untreated. Animals vaccinated at 3 weeks of age showed a significantly higher average daily weight gain and significantly reduced viraemia following PCV2 infection than the respective control groups. This difference was not observed in pigs vaccinated at 1 week of age. Furthermore, only animals vaccinated at 3 weeks of age showed an increased serological response and a higher frequency of IgM-positive animals compared with controls. The data indicated that PCV2 vaccination in the presence of high MDA levels is efficacious when used in 3-week old but not in 1-week old pigs. As the range of MDA titres of pigs vaccinated at both 1 and 3 weeks of age were comparable, the data suggest that PCV2 vaccine efficacy was independent of the level of MDA. It appears that other age-related factors affecting the active and passive transfer of immunity may perhaps have interfered with the efficacy of the vaccine in 1-week old piglets. These findings have implications for future PCV2 vaccine testing and administration strategies.


Subject(s)
Circoviridae Infections/veterinary , Circovirus/immunology , Immunity, Maternally-Acquired/immunology , Swine Diseases/prevention & control , Swine Diseases/virology , Viral Vaccines/administration & dosage , Age Factors , Animals , Animals, Newborn , Antibodies, Viral/blood , Antibodies, Viral/immunology , Circoviridae Infections/prevention & control , Female , Male , Random Allocation , Sus scrofa , Swine , Swine Diseases/immunology , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/immunology , Viral Vaccines/immunology , Viremia/prevention & control , Viremia/veterinary
4.
Int J Radiat Oncol Biol Phys ; 87(1): 88-93, 2013 Sep 01.
Article in English | MEDLINE | ID: mdl-23790772

ABSTRACT

PURPOSE: To evaluate, in a phase 1 study, the safety of neoadjuvant whole-pelvis radiation therapy (RT) administered immediately before radical prostatectomy in men with high-risk prostate cancer. METHODS AND MATERIALS: Twelve men enrolled and completed a phase 1 single-institution trial between 2006 and 2010. Eligibility required a previously untreated diagnosis of localized but high-risk prostate cancer. Median follow-up was 46 months (range, 14-74 months). Radiation therapy was dose-escalated in a 3 × 3 design with dose levels of 39.6, 45, 50.4, and 54 Gy. The pelvic lymph nodes were treated up to 45 Gy with any additional dose given to the prostate and seminal vesicles. Radical prostatectomy was performed 4-8 weeks after RT completion. Primary outcome measure was intraoperative and postoperative day-30 morbidity. Secondary measures included late morbidity and oncologic outcomes. RESULTS: No intraoperative morbidity was seen. Chronic urinary grade 2+ toxicity occurred in 42%; 2 patients (17%) developed a symptomatic urethral stricture requiring dilation. Two-year actuarial biochemical recurrence-free survival was 67% (95% confidence interval 34%-86%). Patients with pT3 or positive surgical margin treated with neoadjuvant RT had a trend for improved biochemical recurrence-free survival compared with a historical cohort with similar adverse factors. CONCLUSIONS: Neoadjuvant RT is feasible with moderate urinary morbidity. However, oncologic outcomes do not seem to be substantially different from those with selective postoperative RT. If this multimodal approach is further evaluated in a phase 2 setting, 54 Gy should be used in combination with neoadjuvant androgen deprivation therapy to improve biochemical outcomes.


Subject(s)
Neoadjuvant Therapy/methods , Prostatectomy , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms/surgery , Aged , Disease-Free Survival , Humans , Lymphatic Irradiation/methods , Male , Middle Aged , Neoadjuvant Therapy/adverse effects , Pelvis , Preoperative Care , Prostate-Specific Antigen/blood , Prostatic Neoplasms/blood , Prostatic Neoplasms/pathology , Radiotherapy, Adjuvant/adverse effects , Radiotherapy, Adjuvant/methods , Radiotherapy, Conformal , Urethral Stricture/etiology , Urinary Incontinence/etiology
5.
Semin Oncol ; 39(5): 588-97, 2012 Oct.
Article in English | MEDLINE | ID: mdl-23040255

ABSTRACT

Deeply invasive bladder cancer, representing approximately 20% of incident cases, is cured by radical cystectomy or radiotherapy in less than 50% of cases. In an effort to improve cure rates, based on objective response rates in metastatic disease of 40%-70% from combination chemotherapy regimens, systemic chemotherapy has been incorporated into programs of definitive treatment for this disease. Several randomized trials and a meta-analysis have confirmed a survival benefit from neoadjuvant chemotherapy followed by definitive local treatment, reflecting both median survival figures and cure rates. Despite several promising phase II trials, no randomized trial of classical adjuvant chemotherapy for bladder cancer has demonstrated an overall survival benefit, despite increments in disease-free survival. Molecular prognostication has been studied in an effort to improve the utility of systemic therapy for invasive non-metastatic bladder cancer, but randomized trials have not shown associated survival benefit. Despite level 1 evidence of a survival benefit from neoadjuvant MVAC (methotrexate, vinblastine, doxorubicin [Adriamycin], cisplatin) or cisplatin, methotrexate, and vinblastine (CMV) chemotherapy, more than 50% of incident cases do not receive such treatment.


Subject(s)
Chemotherapy, Adjuvant , Neoadjuvant Therapy , Urinary Bladder Neoplasms/drug therapy , Humans , Urinary Bladder Neoplasms/therapy
6.
Brachytherapy ; 11(6): 483-8, 2012.
Article in English | MEDLINE | ID: mdl-21937283

ABSTRACT

PURPOSE: Prostate brachytherapy is an increasingly used treatment option for low- to intermediate-risk prostate cancer (PCa). However, patients with preexisting lower urinary tract symptoms (LUTS) and PCa, who would otherwise be good brachytherapy candidates, are often contraindicated because of the risk of postoperative urinary morbidity. We report our clinical experience with limited transurethral resection of the prostate (LTURP) and/or transurethral incision of the prostate (TUIP) months before brachytherapy to treat patients with LUTS and low- to intermediate-risk PCa. METHODS AND MATERIALS: Of 258 men undergoing prostate brachytherapy at our institution between 1998 and 2011, 42 were treated with planned LTURP and/or TUIP well before (mean, 5.7 months) seed implantation. Transurethral surgery was considered before brachytherapy for patients who at presentation required α-blocker therapy for LUTS, had an International Prostate Symptom Score greater than 14 off α-blockers, or had an elevated postvoid residual (>100 mL). Patients only proceeded to brachytherapy once LUTS resolved. RESULTS: All 42 patients in our series underwent TUIP (25), LTURP (7), or TUIP/LTURP (10) with mean 5.7 months before prostate brachytherapy for low- or intermediate-risk PCa. Mean International Prostate Symptom Score, peak flow rate, and postvoid residual significantly improved after transurethral surgery, and improvement persisted at the latest followup. No patient developed retention, urethral necrosis, or urinary incontinence after transurethral surgery or brachytherapy (median followup, 39 months and range, 1-121). CONCLUSIONS: Planned LTURP and/or TUIP more than 4 months before brachytherapy is a safe and effective treatment strategy for men with LUTS and low- to intermediate-risk PCa.


Subject(s)
Brachytherapy/statistics & numerical data , Postoperative Complications/epidemiology , Prostatectomy/statistics & numerical data , Prostatic Neoplasms/epidemiology , Prostatic Neoplasms/radiotherapy , Urologic Diseases/epidemiology , Aged , Brachytherapy/instrumentation , Comorbidity , Humans , Male , Minimally Invasive Surgical Procedures/methods , Minimally Invasive Surgical Procedures/statistics & numerical data , North Carolina/epidemiology , Prevalence , Prostatectomy/methods , Prostheses and Implants/statistics & numerical data , Prosthesis Implantation/methods , Risk Factors , Treatment Outcome , Urethra/surgery
7.
Arch Intern Med ; 167(17): 1892-8, 2007 Sep 24.
Article in English | MEDLINE | ID: mdl-17893311

ABSTRACT

BACKGROUND: To our knowledge, verum acupuncture has never been directly compared with sham acupuncture and guideline-based conventional therapy in patients with chronic low back pain. METHODS: A patient- and observer-blinded randomized controlled trial conducted in Germany involving 340 outpatient practices, including 1162 patients aged 18 to 86 years (mean +/- SD age, 50 +/- 15 years) with a history of chronic low back pain for a mean of 8 years. Patients underwent ten 30-minute sessions, generally 2 sessions per week, of verum acupuncture (n = 387) according to principles of traditional Chinese medicine; sham acupuncture (n = 387) consisting of superficial needling at nonacupuncture points; or conventional therapy, a combination of drugs, physical therapy, and exercise (n = 388). Five additional sessions were offered to patients who had a partial response to treatment (10%-50% reduction in pain intensity). Primary outcome was response after 6 months, defined as 33% improvement or better on 3 pain-related items on the Von Korff Chronic Pain Grade Scale questionnaire or 12% improvement or better on the back-specific Hanover Functional Ability Questionnaire. Patients who were unblinded or had recourse to other than permitted concomitant therapies during follow-up were classified as nonresponders regardless of symptom improvement. RESULTS: At 6 months, response rate was 47.6% in the verum acupuncture group, 44.2% in the sham acupuncture group, and 27.4% in the conventional therapy group. Differences among groups were as follows: verum vs sham, 3.4% (95% confidence interval, -3.7% to 10.3%; P = .39); verum vs conventional therapy, 20.2% (95% confidence interval, 13.4% to 26.7%; P < .001); and sham vs conventional therapy, 16.8% (95% confidence interval, 10.1% to 23.4%; P < .001. CONCLUSIONS: Low back pain improved after acupuncture treatment for at least 6 months. Effectiveness of acupuncture, either verum or sham, was almost twice that of conventional therapy.


Subject(s)
Acupuncture Therapy/methods , Low Back Pain/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Chronic Disease , Double-Blind Method , Female , Germany , Humans , Male , Middle Aged , Pain Measurement , Surveys and Questionnaires , Treatment Outcome
8.
Am J Obstet Gynecol ; 197(2): 205.e1-5; discussion 205.e5-7, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17689652

ABSTRACT

OBJECTIVE: The objective of the study was to determine the feasibility of weekly carboplatin/paclitaxel with radiation therapy (RT) in the primary treatment of cervical cancer. STUDY DESIGN: Women diagnosed with stage IB-1 to stage IVA untreated primary cervical cancer were eligible. Carboplatin (area under the curve = 2.0) and paclitaxel 40 mg/m2 were administered weekly for 6 weeks with pelvic RT. Brachytherapy was completed after pelvic RT. Acute toxicities and response to treatment were assessed. RESULTS: Twenty-two evaluable patients were enrolled. The median duration of follow-up was 23 months. Carboplatin (mean dose 245 mg) and paclitaxel (mean dose 70 mg) were successfully administered in 97% and 90% of planned treatments, respectively. Median time to complete external radiation therapy was 36.6 days (25-57 days). Grade 3/4 hematologic or gastrointestinal toxicity was unusual. The complete response rate 3 months after completion of therapy was 91%. The estimated 3-year progression-free survival is 70% and overall survival is 65%. CONCLUSION: Weekly carboplatin/paclitaxel and RT is a reasonable treatment regimen for cervical cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Uterine Cervical Neoplasms/therapy , Adult , Aged , Brachytherapy , Carboplatin/administration & dosage , Carboplatin/adverse effects , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Middle Aged , Paclitaxel/administration & dosage , Paclitaxel/adverse effects , Pelvis/radiation effects , Uterine Cervical Neoplasms/mortality
9.
J Altern Complement Med ; 12(8): 733-42, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17034279

ABSTRACT

BACKGROUND: In the nationwide German Acupuncture Trials (GERAC), verum acupuncture, mirroring the Traditional Chinese Medicine (TCM) acupuncture style, was tested against sham acupuncture and guideline standard therapy for the entities classified in the West as chronic low back pain (LBP) and gonarthrosis (GON). OBJECTIVE: The objective was to develop broadly consensual acupuncture and control protocols for the treatment of LBP and GON in the GERAC trials. METHODOLOGY: Extensive literature study and consultation with acupuncture experts were consulted. Personal interviews, both free and structured, e-mail discussions, and phone conferences were used as well. RESULTS: Broadly consensual acupuncture protocols for LBP and GON for verum and invasive sham acupuncture were developed. They included semistandardized point combinations with clearly described point selection rules based on TCM acupuncture diagnosis. A procedure was developed to help ensure homogenous treatment quality in a large multicenter trial. CONCLUSIONS: With 1162 randomized patients for LBP and 1039 patients for GON, the GERAC study design allowed acupuncture to be tested in a naturalistic environment. The rigorous study design and large number of physician investigators guaranteed a high external validity for the results. The results will help determine the significance of Chinese acupuncture in the context of Western medicine for the treatment of LBP and GON.


Subject(s)
Acupuncture Therapy/standards , Critical Pathways/organization & administration , Low Back Pain/therapy , Osteoarthritis, Knee/therapy , Randomized Controlled Trials as Topic/standards , Acupuncture Points , Evidence-Based Medicine/standards , Female , Germany , Humans , Male , Multicenter Studies as Topic/standards , Practice Guidelines as Topic/standards , Research Design , Treatment Outcome
10.
JAMA ; 290(19): 2573-80, 2003 Nov 19.
Article in English | MEDLINE | ID: mdl-14625334

ABSTRACT

CONTEXT: Extracorporeal shock wave therapy (ESWT) has been used to treat calcific tendonitis of the shoulder, but trials of ESWT for this purpose have had methodological deficiencies and thus there is limited evidence for its effectiveness. OBJECTIVE: To determine whether fluoroscopy-guided ESWT improves function, reduces pain, and diminishes the size of calcific deposits in patients with chronic calcific tendonitis of the shoulder. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized, placebo-controlled trial conducted between February 1997 and March 2001 among 144 patients (of 164 screened) recruited from referring primary care physicians, orthopedic surgeons, and sports physicians in 7 orthopedic departments in Germany and Austria. INTERVENTIONS: Either high-energy ESWT, low-energy ESWT, or placebo (sham treatment). The 2 ESWT groups received the same cumulative energy dose. Patients in all 3 groups received 2 treatment sessions approximately 2 weeks apart, followed by physical therapy. MAIN OUTCOME MEASURES: The primary end point was the change in the mean Constant and Murley Scale (CMS) score from baseline to 6 months after the intervention. Secondary end points were changes in the mean CMS scores at 3 and 12 months, as well as changes in self-rated pain and radiographic change in size of calcific deposits at 3, 6, and 12 months. RESULTS: Of 144 patients enrolled, all completed treatment as randomized and 134 completed the 6-month follow-up. Both high-energy and low-energy ESWT resulted in significant improvement in the 6-month mean (95% confidence interval [CI]) CMS score compared with sham treatment (high-energy ESWT: 31.0 [26.7-35.3] points; low-energy ESWT: 15.0 [10.2-19.8] points; sham treatment: 6.6 [1.4-11.8] points; P<.001 for both comparisons). Patients who received high-energy ESWT also had significant 6-month CMS improvements compared with those who received low-energy ESWT (P<.001). We found similar results for both the 3-month and 12-month CMS comparisons, as well as for self-rated pain and radiographic changes at 3, 6, and 12 months. CONCLUSIONS: Both high-energy and low-energy ESWT appeared to provide a beneficial effect on shoulder function, as well as on self-rated pain and diminished size of calcifications, compared with placebo. Furthermore, high-energy ESWT appeared to be superior to low-energy ESWT.


Subject(s)
High-Energy Shock Waves/therapeutic use , Rotator Cuff , Tendinopathy/therapy , Calcinosis , Chronic Disease , Double-Blind Method , Female , Fluoroscopy , Humans , Male , Middle Aged , Rotator Cuff/diagnostic imaging , Rotator Cuff/pathology , Tendinopathy/diagnostic imaging , Tendinopathy/pathology
11.
J Altern Complement Med ; 9(5): 763-70, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14629854

ABSTRACT

BACKGROUND: The efficacy of acupuncture treatment for chronic low-back pain has not been reliably proven because of a lack of good quality studies, leading to the necessity of developing the German Acupuncture Trial for Chronic Low-Back Pain (GERAC-cLBP) study. OBJECTIVE: The aim is to assess the effectiveness of traditional Chinese acupuncture for chronic low-back pain compared to sham acupuncture and with a conventional standard therapy. METHODS: This trial is a nationwide, multicenter, randomized, prospective, partially blinded study. The primary endpoint is the success rate after 6 months. Success is defined as an improvement of 33% or more of three pain-related items on the Van-Korff Pain Score or an improvement of 12% or more in the disability measured by the Hanover Functional Ability Questionnaire. Assessment of the effectiveness of the blinding of patients to the form of acupuncture they received will be conducted. All clinical endpoints are assessed centrally by blinded independent observers. The sample size, with a total of 1062 patients to be enrolled, is based on power calculations. Independent central randomization, data collection, data processing, and statistical analysis are provided. Success rates will be tested for differences using two-sided Fisher exact tests. In the primary analysis, all tests will be carried out on the basis of the intention-to-treat principle. Secondary analyses will be conducted according to protocol approaches. TRIAL STATUS: The pilot phase of the trial started in February 2002, the estimated duration of the study is 2.5 years. Enrollment is anticipated to be completed in the winter of 2003. CONCLUSION: The GERAC-cLBP study is currently the world's largest controlled trial of the effectiveness of acupuncture treatment for low-back pain. It will contribute to the evaluation of efficacy by means of evidence based medicine.


Subject(s)
Acupuncture Therapy , Low Back Pain/therapy , Acupuncture Therapy/methods , Chronic Disease , Clinical Protocols/standards , Double-Blind Method , Female , Germany , Humans , Male , Prospective Studies , Research Design/standards , Time Factors
12.
BMJ ; 327(7406): 75, 2003 Jul 12.
Article in English | MEDLINE | ID: mdl-12855524

ABSTRACT

OBJECTIVE: To determine the effectiveness of extracorporeal shock wave therapy compared with placebo in the treatment of chronic plantar fasciitis. DESIGN: Randomised, blinded, multicentre trial with parallel group design. SETTING: Nine hospitals and one outpatient clinic in Germany. PARTICIPANTS: 272 patients with chronic plantar fasciitis recalcitrant to conservative therapy for at least six months: 135 patients were allocated extracorporeal shock wave therapy and 137 were allocated placebo. MAIN OUTCOME MEASURES: Primary end point was the success rate 12 weeks after intervention based on the Roles and Maudsley score. Secondary end points encompassed subjective pain ratings and walking ability up to a year after the last intervention. RESULTS: The primary end point could be assessed in 94% (n=256) of patients. The success rate 12 weeks after intervention was 34% (n=43) in the extracorporeal shock wave therapy group and 30% (n=39) in the placebo group (95% confidence interval - 8.0% to 15.1%). No difference was found in the secondary end points. Few side effects were reported. CONCLUSIONS: Extracorporeal shock wave therapy is ineffective in the treatment of chronic plantar fasciitis.


Subject(s)
Fasciitis, Plantar/therapy , Lithotripsy/methods , Algorithms , Double-Blind Method , Female , Follow-Up Studies , Humans , Lithotripsy/adverse effects , Male , Middle Aged
13.
Gynecol Oncol ; 89(3): 499-503, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12798718

ABSTRACT

OBJECTIVES: The objectives were to determine the acute toxicities of concurrent carboplatin and radiation therapy in the primary treatment of cervix cancer and to ascertain the antitumor activity of this regimen. METHODS: Patients with stage IB-1 to IVA untreated primary cervix cancers were eligible for enrollment into this study. Carboplatin was administered on a weekly basis with external radiation therapy (ERT). Low-dose brachytherapy was given after completion of ERT. Acute toxicities and response to treatment were assessed. RESULTS: Thirty-one evaluable patients were enrolled. The majority of patients had early stage disease. Carboplatin was successfully administered in 175 out of 186 (94%) planned treatments. All patients completed the prescribed course of radiation therapy. The mean treatment time was 50 days (36-73). There were no treatment delays for neutropenia or gastrointestinal toxicity. No patient was hospitalized for treatment related toxicities. Gastrointestinal toxicity equivalent to grade 3 or 4 was not reported. The objective tumor response based on physical exam findings and computed tomography measurements was 90%. CONCLUSION: Patients with cervix cancer can be treated on schedule with concurrent carboplatin and pelvic radiation therapy. This regimen is well tolerated and produces excellent response rates.


Subject(s)
Antineoplastic Agents/therapeutic use , Carboplatin/therapeutic use , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/radiotherapy , Adenocarcinoma/drug therapy , Adenocarcinoma/radiotherapy , Antineoplastic Agents/adverse effects , Brachytherapy/adverse effects , Brachytherapy/methods , Carcinoma, Adenosquamous/drug therapy , Carcinoma, Adenosquamous/radiotherapy , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/radiotherapy , Combined Modality Therapy/adverse effects , Female , Humans , Neoplasm Staging , Radiotherapy/adverse effects
14.
Arch Orthop Trauma Surg ; 122(9-10): 518-21, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12483333

ABSTRACT

BACKGROUND: Despite the extensive use of extracorporeal shock wave therapy (ESWT) in the therapy of chronic tendopathies, the biological mechanisms of its antinociceptive effects are still unclear. METHODS: In this study we addressed the question of whether the clinically described, long-lasting effect of ESWT is mediated by changes in the activity of spinal cord neurones. As a marker for neuronal activity which is also able to interfere with the molecular expression pattern of neurones, the expression of the inducible transcription factor c-Fos was analysed in the animal model of the rat. Despite application of different energy levels, the analysis of c-Fos protein expression at an early (4 h) and late (72 h) time point after ESWT revealed no visible changes in immunoreactivity in the dorsal horn of the spinal cord. Additionally, there was no change in c-Fos protein and its gene expression c-Fos mRNA in the treatment area of the paw. RESULTS AND CONCLUSION: We conclude that ESWT with an energy flux dose up to 0.33 mJ/mm(2)does not modify neuronal activity. Since the application of ESWT showed no significant changes in the immunoreactivity of c-Fos, it is therefore unlikely that ESWT triggers stimulation-produced analgesia via activation of peripheral nerves.


Subject(s)
High-Energy Shock Waves/therapeutic use , Neurons/metabolism , Proto-Oncogene Proteins c-fos/metabolism , Animals , Immunohistochemistry , In Situ Hybridization , Models, Animal , Rats , Spinal Cord/cytology
16.
Strahlenther Onkol ; 178(6): 314-20, 2002 Jun.
Article in German | MEDLINE | ID: mdl-12122787

ABSTRACT

BACKGROUND AND AIM: Supraspinatus tendinitis is usually treated by antiinflammatoric drugs, local injections, physiotherapy or low-dose irradiation. A novel approach is the use of Extracorporeal Shock Wave Therapy (ESWT) if conservative therapies have failed. So far there has been no controlled study comparing the effectiveness of ESWT with an established conservative method of therapy such as X-ray stimulation radiotherapy. PATIENTS AND METHOD: 30 patients with chronic supraspinatus tendinitis were admitted into the prospective randomized study. After randomization the patients were treated either with X-ray stimulation radiotherapy with 6 x 0.5 Gy on the ICRU reference point (1 fraction/day) with cobalt 60 gamma rays or three times with 2000 pulses (energy flux density ED+ 0.1 mJ/mm2) in 1 week intervals using a Storz Minilith SL1. Primary endpoint was the age-corrected constant score 3 months after intervention. RESULTS: Acute side effects caused by the irradiation were not observed, as expected. One patient described pain and one patient showed a moderate skin irritation after ESWT. In the radiotherapy group average the age-corrected constant score improved from 47.6 through 79.5 points to 87.4 points. In the ESWT group it rose from 50.1 points before ESWT to 91.4 points after 12 weeks and 97.8 after 52 weeks. CONCLUSION: No statistically significant differences were proven between ESWT and radiotherapy. ESWT appears to be equivalent but not superior to radiotherapy in treating chronic supraspinatus tendinitis syndrome. A comprehensive randomized study is, however, necessary to ensure the equivalence of ESWT.


Subject(s)
Lithotripsy , Shoulder Impingement Syndrome/radiotherapy , Tendinopathy/radiotherapy , Adult , Aged , Cobalt Radioisotopes/therapeutic use , Dose Fractionation, Radiation , Female , Humans , Male , Middle Aged , Pain Measurement , Patient Satisfaction , Prospective Studies , Radioisotope Teletherapy , Radiotherapy Dosage , Shoulder Impingement Syndrome/diagnosis , Tendinopathy/diagnosis
17.
Clin Orthop Relat Res ; (397): 323-31, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11953624

ABSTRACT

A controlled prospective randomized study was designed to analyze the effect of extracorporeal shock wave therapy on calcifying tendinopathy of the shoulder focused on the calcified area or the origin of the supraspinatus tendon. Fifty patients were included in the study and were treated with a Storz Minilith Sl-1 shock wave generator. The first group of patients received 4000 impulses (positive energy flux density, 0.78 mJ/mm2) in two treatment sessions after receiving local anesthesia at the origin of the supraspinatus tendon. Patients in the second group received extracorporeal shock wave therapy at the calcified area. Follow-ups were done 12 weeks and 1 year after treatment by an independent observer. An increase of function and a reduction of pain occurred in both groups. Statistical analyses showed a significant superiority of extracorporeal shock wave application at the calcified area in the primary end point (Constant and Murley score). Therefore, exact fluoroscopic focusing of extracorporeal shock wave therapy at the calcific deposit for treatment of calcifying tendinopathy of the supraspinatus muscle is recommended. Based on these results, extracorporeal shock wave application should be focused fluoroscopically with appropriate shock wave generators.


Subject(s)
Calcinosis/therapy , Lithotripsy , Shoulder Joint , Tendinopathy/therapy , Adult , Aged , Female , Fluoroscopy , Humans , Lithotripsy/methods , Male , Middle Aged , Prospective Studies , Treatment Outcome
18.
J Orthop Sci ; 7(1): 97-101, 2002.
Article in English | MEDLINE | ID: mdl-11819140

ABSTRACT

The analgesic effects of high-energy extracorporeal shock wave therapy (ESWT) were discovered by chance during its application for urolithiasis and for bone pseudarthrosis. Despite the extensive use of ESWT, the mechanisms of its antinociceptive effects are still unclear. A gate control mechanism and other antinociceptive mechanisms have been postulated. The aim of this study was to investigate the possible influence of low-energy ESWT on the expression of the transmitters substance P (SP) and calcitonin gene-related peptide (CGRP) in the lumbar spinal cord of the rat. Immunohistochemical analysis of the expression of the neuropeptides CGRP and SP was performed in rats treated either once with 1000 impulses or three times with 1000 impulses, with two different energy flux densities being used (0.043 and 0.11 mJ/mm2). The animals were killed either 4 or 72 h after the ESWT. No regulatory effect of ESWT on the expression of SP or CGRP in the dorsal horns was found. Because the application of ESWT showed no significant changes in the sensory system, it is unlikely that the application of ESWT triggers the endogenous pain control system of the rat through hyperstimulation analgesia. Furthermore, these results show that low-energy ESWT had no side effects on the rat spinal cord.


Subject(s)
Calcitonin Gene-Related Peptide/metabolism , Lithotripsy/methods , Pain Management , Pain/physiopathology , Spinal Cord/metabolism , Spinal Cord/pathology , Substance P/metabolism , Animals , Disease Models, Animal , Female , Immunohistochemistry , Lumbar Vertebrae , Male , Rats , Rats, Wistar , Reference Values , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...